Press & Media

PlexBio Receives IntelliPlex™ 1000 Market Approval


Taipei, Taiwan- August 16, 2017- PlexBio Co., Ltd., an emerging multi-national diagnostic company with an industry-leading multiplex diagnostic platform, has received certification of market approval for the IntelliPlex™ 1000 πCode Processor from the Food and Drug Administration of the Taiwan Ministry of Health and Welfare. The certification means that the processor is approved for sale on the Taiwan market as a Class I device.

 

PlexBio Chief Technology Officer Dr. Chin-Shiou Huang said, “This market approval, complements the earlier approval of the PlexBio™ 100 Fluorescent Analyzer, and we now are able to provide a complete diagnostic instrumentation platform for our customers in Taiwan. This compact device has been designed to enhance performance and customer convenience. And with its multiple functions, we expect the IntelliPlex platform to have a significant impact in the Taiwan clinical market and beyond.”

 

PlexBio’s πCode™ MicroDisc technology is currently the largest multiplexing platform commercially available, capable of generating over 16,000 circular image patterns. Each image pattern corresponds to an individual target which can be detected simultaneously via the advanced optical imaging and fluorescence capabilities of the PlexBio™ 100. Prior to detection, the assay undergoes hybridization, washing, adding of fluorescence steps by using IntelliPlex™ 1000.

 

 

By using this higher order multiplexing platform, PlexBio is able to offer highly sensitive and specific results for both immuno and molecular diagnostic formats from very low input sample volumes - which saves time and labor. Multiple tests are currently undergoing clinical evaluation in hospital and clinical labs in the APAC region and the company expects the IntelliPlex™ and DigiPlex instrument systems to achieve the CE-Mark in the second half of 2017.

 

 

About PlexBio Co., Ltd.:The company established in May 2010, designs, develops and manufactures IVD products and instrumentation from its headquarters in Taipei, Taiwan and its affiliate location in Jiangsu Province, China. PlexBio has also established an Innovative Technology Center in South San Francisco, CA, USA. The company is a listed company at Taiwan emerging stock market. http://www.plexbio.com

 

 

 

Contact Information: 

PlexBio, Co., Ltd. 

Address: 6F-1, No. 351, Yangguang St.,

Neihu District, Taipei City 11491, Taiwan 

Tel: +886-2-2627-5878

Fax: +886-2-2627-5979

E-mail: contact@plexbio.com